Assessing health-related quality of life of patients with colorectal cancer using EQ-5D-5L: a cross-sectional study in Heilongjiang of China

Huang, Weidong; Yang, Jian; Liu, Yang; Liu, George; Zhang, Xin; Fu, Wang; Shi, Limei; Liu, Guoxiang

doi:10.1136/bmjopen-2018-022711

Cited by 43 publications

(62 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings did not indicate that more advanced stages of CRC were associated with a lower HRQoL. As pointed out by Huang et al [ 17 ], the evidence for the association between HRQoL and the stage of CRC from the literature is contradictory.…”

Section: Discussioncontrasting

confidence: 86%

“…Huang and colleagues [ 17 ] assessed the HRQoL of 300 newly diagnosed patients with CRC in China’s Heilongjiang province. On average, the included patients were younger (mean age 59 vs 66 years) and diagnosed at an earlier tumor stage (stage IV 12% vs 67%) than in our study.…”

Section: Discussionmentioning

confidence: 99%

“…On the contrary, the review showed that heart disease had a significant role on overall HRQoL [ 21 ], which was not confirmed in our study. The study by Huang and colleagues [ 17 ] also assessed determinants of HRQoL of patients with CRC using tobit regression. The study found that low HRQoL was associated with more advanced stages of CRC, presence of a stoma, surgery only treatments, and low socioeconomic status.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry

Borchert¹,

Jacob²,

Wetzel

et al. 2020

Health Econ Rev

View full text Add to dashboard Cite

Background The EQ-5D-5L questionnaire is used in oncology to generate health-related quality of life (HRQoL) weights and corresponding health states. The purpose was to explore the relationship between demographic and clinical characteristics and HRQoL among advanced or metastatic colorectal cancer (CRC) patients by linking clinical data of a German CRC registry to self-reported HRQoL measures from the EQ-5D-5L. Methods The study sample included patients with advanced or metastatic CRC currently recruited in the German Tumor Registry Colorectal Cancer. The EQ-5D-5L was administered once to patients who were at the start or at later stages of palliative treatment. Data on comorbidities, disease-specific health states, symptoms, and treatment status were drawn from the registry. Multivariate regression analyses were performed to explore the impact of patient and disease characteristics on HRQoL. Results In total, n = 433 questionnaires were included in the data analysis. Mean age of patients was 66.3 years and 61.2% were male. The mean EQ-5D-5L utility score was 0.82 and the mean EQ-5D-5L VAS score was 62.05. The regression analyses revealed that none of the demographic characteristics and few of the clinical characteristics, such as fatigue and pain, had a significant impact on the HRQoL. Conclusions The study demonstrated a reduced HRQoL of patients with advanced or metastatic CRC when compared to the general population. The symptoms fatigue and pain negatively affected the HRQoL, whereas other characteristics such as age, gender, and comorbidities did not have a significant impact on HRQoL.

show abstract

Section: Discussioncontrasting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry

Borchert¹,

Jacob²,

Wetzel

et al. 2020

Health Econ Rev

View full text Add to dashboard Cite

show abstract

“…In particular, its new version of EQ-5D with five-level scale, namely EQ-5D-5L, has been highly suggested due to its ability to reduce the ceiling effect. The good validity and reliability of EQ-5D-5L in certain chronic conditions have been demonstrated 14–17. However, the relative effects of hypertension and related comorbidity on HRQoL using EQ-5D-5L in HK have been rarely explored.…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life among patients with hypertension: population-based survey using EQ-5D-5L in Hong Kong SAR, China

Wong

Cheung

2019

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo evaluate the effect of hypertension and related comorbidities on the health-related quality of life (HRQoL) using EuroQol 5-dimensions instrument with five-level scale (EQ-5D-5L) Hong Kong (HK) version.DesignData were analysed by a secondary data analysis based on a cross-sectional study assessing experience on public specialist outpatient service.SettingA representative sample was recruited from 26 specialist outpatient clinics in HK.ParticipantsA total of 4528 patients with hypertension aged 18 or above who responded to the survey.InterventionEQ-5D-5L HK was applied to assess the HRQoL. The five-dimension descriptive system and the utility index of EQ-5D-5L were treated as the dependent variable in the current study. Regression modelling was applied to estimate the effect of hypertension and related comorbidities on health-related quality of life.ResultsMore respondents were women (53.9%), aged ≥65 years old (60.1%), and with primary educational attainment or below (52.3%). A total of 1466 respondents (32.4%) also reported suffering from diabetes, heart disease (20.8%), vision problem (1.7%) and cancer (1.5%). In the ordinal least squares model, utility decreased most when patients reported having physical disability associated with hypertension (beta=−0.395, SE=0.047), and 0.128, 0.064, 0.05 and 0.048 for mental problem, cancer, vision problem and heart problem. In the Tobit model, the utility reduced most for comorbidity of physical disability, and then mental problem, cancer, vision problem, heart problem and diabetes. For first part of two-part model, respondents coliving with mental problem were 10% less likely to report a full health. For the second part of two-part model, the respondents with physical disability had 0.294 lower in utility.ConclusionsRespondents with hypertension reported a low EQ-5D utility score. Respondents were women, with a high education, fully employed and living with families reported better HRQoL. There is a significant effect of comorbidity influence on the decreased HRQoL, particularly those with physical disability and mental problem.

show abstract

“…Of all of the dimensions assessed by the QLQ-C30 and the EQ-5D-5L, pain may be the one most closely associated with disease symptoms and treatment efficacy, with less confounding by toxicity of treatment [ 20 – 22 ]. At baseline, the mean score for pain from the QLQ-C30 indicated high levels of pain and < 30% of patients reported no pain or discomfort on the EQ-5D-5L.…”

Section: Discussionmentioning

confidence: 99%

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

et al. 2020

View full text Add to dashboard Cite

Background To evaluate patient-reported outcomes with ramucirumab plus docetaxel, a regimen which improved progression-free survival in platinum-refractory advanced urothelial carcinoma (aUC). Methods RANGE—a randomized, double-blinded, phase 3 trial in patients with platinum-refractory aUC. Ramucirumab (10 mg/kg) plus docetaxel (75 mg/m2) or placebo plus docetaxel were administered every 21 days until disease progression or unacceptable toxicity. Patients received maximum 10 cycles of docetaxel. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and EuroQoL five-dimensions (EQ-5D-5L) were administered at baseline, start of each cycle, and 30-day follow-up visit. A ≥ 10-point change in QLQ-C30 scores was considered meaningful. Rates of improved/stable scores were compared between treatment arms using Fisher’s exact test. Time to deterioration (TtD) was estimated and compared using Kaplan–Meier estimation and log-rank test. Results Of the 530 patients, ~ 97% patients in each arm provided baseline QLQ-C30 data. On-treatment compliance was ≥ 88% for first 8 cycles. Mean baseline QLQ-C30 scores were similar between arms, with global quality of life (QoL), fatigue, pain, and insomnia having greatest impairment. Postbaseline rates of improved/stable QLQ-C30 scores were similar between treatment arms except for greater improvement in pain score with ramucirumab. TtD of QLQ-C30 scales favored ramucirumab arm. Baseline EQ-5D-5L index and visual analogue scale scores were similar between arms, followed by relatively stable on-treatment scores. EQ-5D-5L scores worsened at post-discontinuation follow-up visit. Conclusions Ramucirumab plus docetaxel did not negatively impact QoL compared with docetaxel alone in platinum-refractory aUC. Improved TtD and tumor associated rates of pain favored ramucirumab treatment. Clinical trail registration NCT02426125. https://clinicaltrials.gov/ct2/show/NCT02426125. Date of registration: April 24th 2015

show abstract

Assessing health-related quality of life of patients with colorectal cancer using EQ-5D-5L: a cross-sectional study in Heilongjiang of China

Cited by 43 publications

References 41 publications

Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry

Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry

Health-related quality of life among patients with hypertension: population-based survey using EQ-5D-5L in Hong Kong SAR, China

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Contact Info

Product

Resources

About